Validating headline phrasing and editorial resonance A Director Cashes In Near the Top, but What Remains Matters

Roy D. Baynes, Director at Travere Therapeutics, exercised and sold 4,500 shares for approximately $210,000 on May 5, 2026, reducing his direct holdings by 10.71%. The sale was executed under a pre-arranged 10b5-1 plan adopted in November 2025 and occurred near the stock's 52-week high. Despite cashing in near the top, Baynes retained 37,500 shares worth ~$1.6 million, suggesting continued conviction in the company.

05/10/2026, 9:16 AM • The Motley Fool

Your Kidneys Count: American Kidney Fund Urges Americans to Protect Their Health this Kidney Month

The American Kidney Fund (AKF) is launching its Kidney Month campaign on March 1, 2026, to raise awareness about kidney disease affecting 1 in 7 American adults. The campaign emphasizes early detection and prevention through the 'Kidneys Count' initiative and encourages people to pledge to discuss kidney health with their doctors. AKF will host Kidney Action Week (March 2-5) featuring expert sessions on kidney disease management and treatment options.

02/27/2026, 9:52 AM • GlobeNewswire

TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Encourages Investors and Potential Witnesses to Contact Law Firm

Robbins Geller Rudman & Dowd LLP has launched an investigation into Travere Therapeutics, Inc. for potential violations of U.S. federal securities laws, alleging the biopharmaceutical company and certain executives made materially false and/or misleading statements regarding its business and operations. The firm is seeking investors who suffered losses and potential witnesses to contact them.

01/30/2026, 8:50 PM • GlobeNewswire

TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm

Robbins Geller Rudman & Dowd LLP has launched an investigation into Travere Therapeutics, Inc. for potential violations of U.S. federal securities laws. The investigation examines whether Travere and its executives made materially false or misleading statements regarding the company's business and operations. The law firm is seeking investors who suffered losses and potential witnesses to contact them.

01/13/2026, 6:58 PM • GlobeNewswire

Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday

Travere Therapeutics stock surged nearly 14% on Wednesday following bullish analyst notes. Jefferies analyst Maury Raycroft identified Travere as a potential takeover candidate and highlighted its drug Filspari as having blockbuster potential. Cantor Fitzgerald reported that the FDA appears flexible on approving Filspari for treating focal segmental glomerulosclerosis (FSGS), with an FDA decision expected by January 13, 2026.

12/24/2025, 6:31 PM • The Motley Fool

Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance

Ligand Pharmaceuticals announced 2026 full year revenue guidance of $245-$285 million, representing a 15% core revenue growth, with strong expectations for royalty revenue from key pharmaceutical products.

12/09/2025, 7:00 AM • GlobeNewswire

American Kidney Fund Hosts Third Patient Access Initiative Summit to Address Barriers to Kidney Care and Propose Innovative Solutions

The American Kidney Fund hosted its third annual Patient Access Initiative Summit focusing on innovative kidney care technologies, AI applications, and addressing barriers to kidney disease prevention and treatment.

11/21/2025, 9:00 AM • GlobeNewswire

10 Health Care Stocks With Whale Alerts In Today's Session

Multiple health care stocks experienced significant options trading activity, with various bullish and bearish signals across different companies in the sector.

09/29/2025, 1:35 PM • Benzinga